SCHEMBL2385493

SCHEMBL2385493

CCOC(=O)[C@H](Cc1ccccc1)N(N[C@@H](Cc1ccc(C)c(C)c1)C(=O)O)C(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.42
ACE P12821 2/20 0.42
ITGA4 P13612 1/20 0.40
ITGB7 P26010 1/20 0.40
KMT2A Q03164 1/20 0.38
PTPN1 P18031 1/20 0.38
TP53 P04637 1/20 0.38
KLK5 Q9Y337 1/20 0.38
PSMB8 P28062 2/20 0.37
PSMB5 P28074 2/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
HSD17B10 Q99714 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MMP8 P22894 1/20 0.37
AKT1 P31749 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
CTSS P25774 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2384999 0.93 POLB (0.43) POLBACEITGA4ITGB7KMT2A
SCHEMBL2386632 0.92 ITGA4 (0.45) POLBACEITGA4ITGB7KMT2A
SCHEMBL2387347 0.90 ITGA4 (0.42) ACEITGA4ITGB7L3MBTL1MMP8
SCHEMBL2385838 0.90 ITGA4 (0.42) ACEITGA4ITGB7MMP8AKT1
SCHEMBL2385738 0.90 TP53 (0.44) POLBACEITGA4ITGB7KMT2A
SCHEMBL2385019 0.89 ITGA4 (0.44) ACEITGA4ITGB7MMP8CTSS
SCHEMBL2387887 0.89 ITGA4 (0.42) POLBACEITGA4ITGB7KMT2A
SCHEMBL2386777 0.89 POLB (0.43) POLBACEKMT2ATP53PSMB8
SCHEMBL2388227 0.89 MME (0.42) ACEITGA4ITGB7KMT2AMMP8
SCHEMBL2385883 0.89 TACR1 (0.43) POLBACEITGA4ITGB7KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017378-B2 Method for production of optically active biphenylalanine compound or salt or ester thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-09-13 US disclosed
EP-1980622-B1 METHOD FOR PRODUCTION OF AN OPTICALLY ACTIVE BIPHENYLALANINE COMPOUND OR SALT OR ESTER THEREOF SUMITOMO CHEMICAL CO (JP) 2010-08-18 EP disclosed
US-20090011475-A1 Method For Production of Optically Active Biphenylalanine Compound or Salt or Ester Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-01-08 US disclosed
EP-1980622-A1 METHOD FOR PRODUCTION OF OPTICALLY ACTIVE BIPHENYLALANINE COMPOUND OR SALT OR ESTER THEREOF Sumitomo Chemical Company, Limited (JP) 2008-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090011475-A1 Method For Production of Optically Active Biphenylalanine Compound or Salt or Ester Thereof DNPEP, APEH, PAH POLB 2554/4885ACE 31/4885ITGA4 4819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.